Core Insights - Eli Lilly (LLY.US) is preparing inventory for its experimental oral weight loss drug orforglipron, awaiting a potential FDA approval decision in the coming months [1] - The company reported a pre-market inventory value of $1.5 billion related to orforglipron as of December 31, 2025, up from $548.1 million a year earlier [1] - Orforglipron has received a priority review voucher from the FDA and is expected to gain regulatory approval in Q2 2026 for use in overweight or obese adults [1] Group 1: Clinical Trial Results - In the Phase 3 clinical trial ACHIEVE-1, orforglipron demonstrated a reduction in HbA1c levels by an average of 1.3% to 1.6% in adult patients with type 2 diabetes [2] - Significant weight loss of nearly 8% was observed in the high-dose group by week 40, with the drug administered once daily at doses of 3 mg, 12 mg, and 36 mg [2] - Only the 12 mg and 36 mg dosage groups showed clinically meaningful and statistically significant weight loss compared to placebo [2] Group 2: Competitive Landscape - Novo Nordisk (NVO.US) has established a lead in the oral weight loss drug market with its Wegovy product, which was launched in early January and has over 240,000 patients in the U.S. [3] - The company plans to increase investment in Ireland to produce the oral version of Wegovy for markets outside the U.S. [2] - Despite intensifying price competition in the weight loss drug market, Novo Nordisk aims to leverage its oral medication to regain market dominance and close the gap with Eli Lilly [3]

Core Viewpoint - Viking Therapeutics plans to advance its experimental weight loss drug VK2735 into late-stage research in the third quarter of this year, following positive mid-stage study results indicating effective weight maintenance through a low-dose oral treatment strategy [1] Group 1: Company Developments - Viking Therapeutics' stock rose by 16.3% to $33.2 in pre-market trading [1] - The company emphasizes that the regulatory pathway for VK2735 has advantages over its injectable weight loss drug project, potentially shortening trial duration and reducing trial scale [1] Group 2: Industry Insights - The positive mid-stage research results for VK2735 highlight a growing interest in oral weight loss treatments within the pharmaceutical industry [1]

Core Viewpoint - Novo Nordisk has experienced a strong stock price rebound at the beginning of the year, driven by the impressive prescription performance of its oral weight loss drug Wegovy, outperforming major competitor Eli Lilly [1][3] Group 1: Stock Performance - Novo Nordisk's stock price has increased by approximately 16% year-to-date, while Eli Lilly's stock has declined by about 4% during the same period [3] - The reversal in performance is primarily attributed to Novo Nordisk's "first-mover advantage" in the oral weight loss drug market [3] Group 2: Product Launch and Market Response - Wegovy, the first FDA-approved oral obesity medication, officially entered the market in early January after receiving approval in December [3] - As of the week ending January 23, Wegovy's prescriptions in the U.S. reached 26,109, indicating strong market demand [3] - In its first week, Wegovy received 18,410 prescriptions, and in the second full sales week, the prescription volume exceeded 16,000, showcasing rapid growth [3] Group 3: Competitive Landscape - Over the past two years, Novo Nordisk's stock price had significantly declined, contrasting with Eli Lilly's strong performance due to its capture of approximately 60% of the obesity drug market share [3] - With the rapid uptake of Wegovy, Novo Nordisk is regaining investor confidence [3] - Eli Lilly is still awaiting FDA approval for its oral weight loss drug orforglipron, which may further alter the competitive landscape in the coming months [3]

Core Viewpoint - After two consecutive years of stock price decline, Danish pharmaceutical giant Novo Nordisk (NVO.US) has experienced a strong rebound at the beginning of the new year, driven by the impressive prescription performance of its oral weight loss drug Wegovy, outperforming major competitor Eli Lilly (LLY.US) [1] Group 1: Stock Performance - Novo Nordisk's stock has risen approximately 16% year-to-date, while Eli Lilly's stock has declined about 4% during the same period [1] - The reversal in performance is attributed to Novo Nordisk's "first-mover advantage" in the oral weight loss drug market [1] Group 2: Product Approval and Market Entry - The FDA approved Wegovy tablets for market entry in December last year, making it the first oral obesity drug to receive approval [1] - As of the week ending January 23, Wegovy prescriptions in the U.S. reached 26,109, indicating strong market interest [1] Group 3: Prescription Growth - In its first week on the market, Wegovy received 18,410 prescriptions, and in the second full sales week, the prescription volume exceeded 16,000, showing rapid growth [1] - Novo Nordisk is regaining investor confidence as Wegovy's market presence expands [1] Group 4: Competitive Landscape - Eli Lilly is still awaiting FDA approval for its oral weight loss drug orforglipron, which may further alter the competitive landscape in the coming months [2]

诺和诺德的 Wegovy 药片在上市后的第一个完整星期内，在美国的处方量超过了 18,000 次。分析师援 引 IQVIA 数据表示，这为口服 减肥药竞争开创了一个令人鼓舞的开端。至少有两位分析师说，随着制 药商转向现金支付的消费模式，处方数据预示着该药的早期吸收率很高，而且领先于其他GLP-1药物的 上市。 ...

诺和诺德股价大涨。 口服剂型被普遍认为是减肥药市场的下一个增长引擎。高盛分析师曾在报告中预测，到2030年，口服药可能占据全球减肥药市场24%的份额，规模约220 亿美元。 中概股表现较为疲软，截至发稿，纳斯达克中国金龙指数跌超1%。热门中概股中，阿特斯太阳能跌超8%，小鹏汽车、晶科能源、万国数据、禾赛科技等 跌超3%，小马智行、名创优品、金山云、哔哩哔哩、蔚来、腾讯控股ADR等跌超2%，百度集团、小米集团ADR、京东集团、阿里巴巴等跌超1%。 这份数据远超3.2%的市场预期，令市场担心美联储在2026年初降息的可能性降低。芝加哥商品交易所美联储观察工具的数据显示，报告发布后，联邦基 金利率期货交易员略微增加了押注，认为美联储将在明年1月和3月的议息会议上维持利率不变。 个股方面，诺和诺德大涨，盘中一度涨超10%。消息面上，美国FDA批准了诺和诺德的首款口服GLP-1减肥药。诺和诺德方面表示，这款口服药预计将于 2026年初正式上市，起始剂量的现金价格为每月149美元。公司同时表示，对于拥有保险的患者，在涵盖所有剂量的情况下，每月费用可能低至25美元。 诺和诺德首席执行官Mike Doustdar在声明中表示 ...

周二，诺和诺德(NVO.US)盘前涨超8%，报52.29美元。消息面上，美国FDA批准了诺和诺德的首款口服 GLP-1减肥药，使其在与礼来的竞争中抢得先机。这款Wegovy的口服版本将于明年1月初在美国上市， 起始现金价为每月149美元。临床数据显示其可帮助患者减重高达16.6%，并能降低心血管风险。 据报道，礼来公司自己的口服减肥药预计将在明年3月获批。这意味着诺和诺德拥有了几个月的宝贵窗 口期，以巩固其在口服药市场的首发优势。 ...

美国FDA批准了诺和诺德的首款口服GLP-1减肥药，使其在与礼来的激烈竞争中抢得先机，公司股价盘后一度应声大涨10%。这款Wegovy的口服版本 将于明年1月初在美国上市，起始现金价为每月149美元。临床数据显示其可帮助患者减重高达16.6%，并能降低心血管风险。礼来的同类口服药预计在3 月获批。 抢在礼来之前，诺和诺德在美国的减肥药市场竞争中扳回一局。 12月22日周一，美国食品药品监督管理局（FDA）批准了丹麦制药巨头诺和诺德的首款GLP-1类口服减肥药。这款新药是其明星注射产品Wegovy的口 服版本，为数百万寻求更便捷治疗方案的肥胖症患者带来了新选择。 根据诺和诺德的声明，这款口服新药将于明年1月初在美国上市。公司披露了初步的定价策略， 起始剂量的现金支付价格为每月149美元。公司同时表 示，对于拥有保险的患者，在涵盖所有剂量的情况下，每月费用可能低至25美元。 更高剂量的定价以及更详细的保险覆盖和患者节省计划将在临近上 市时公布。 诺和诺德首席执行官Mike Doustdar在声明中表示："Wegovy口服药为患者提供了一个全新、便捷的治疗选择，可以帮助他们开始或继续他们的减重旅 程。"他强调，目前 ...

Core Viewpoint - Eli Lilly (LLY) shares rose by 0.7% following the announcement of positive results from a Phase 3 clinical trial for orforglipron, which helps maintain weight loss in patients transitioning from injectable drugs Wegovy and Zepbound. The drug has been submitted for FDA approval and has received priority review status [1][2]. Group 1 - Eli Lilly's stock increased by 0.7% on Friday morning [1][2]. - The Phase 3 clinical trial demonstrated that orforglipron can help maintain weight loss effects after patients switch from Wegovy and Zepbound [1][2]. - The company has submitted orforglipron for FDA approval and it has been granted priority review status [1][2].

公司表示，该研究达到了主要终点及所有关键次要终点。安全性和耐受性方面，orforglipron的表现与此 前三期研究结果一致，符合每日一次口服给药的安全特征。 周四，礼来(LLY.US)股价一度涨超3%，截至发稿，该股涨幅缩窄至1.84%，报1061美元。消息面上，该 公司宣布，其口服减肥药orforglipron在一项三期临床试验中显示出优于对照的体重维持效果，适用于此 前已使用注射型减肥药(包括公司自身的Zepbound以及诺和诺德(NVO.US)的Wegovy)的肥胖或超重成年 人。 礼来援引ATTAIN-MAINTAIN试验的顶线数据称，在为期52周的研究中，从Wegovy或Zepbound转换为 orforglipron的患者，基本维持了此前通过注射药物获得的减重成果。数据显示，与对照相比，从 Wegovy转换的患者体重平均差异为0.9公斤，从Zepbound转换的患者体重平均差异为5.0公斤。 ...